Back to search results
NCT06925685

Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Enrolling by Invitation
Not specifiedAll AgesObservational
Allogene Therapeutics
~50 participants
Updated 2025-04-13 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEs
Measured over Up to 15 years post treatment with allogeneic CAR T-cell product
+2 more outcomes measured

Conditions

Hematologic Malignancies
Solid Tumors

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT06925685

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Circuit Clinical

    Buffalo, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Allogene Study Director · STUDY_DIRECTOR · Allogene Therapeutics, Inc.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study

Exclusion

Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor

What this trial measures

  • Incidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEsUp to 15 years post treatment with allogeneic CAR T-cell product
  • Overall survival (OS)Up to 15 years post treatment with allogeneic CAR T cell product
  • Presence of replication competent lentivirus (RCL) in bloodUp to 15 years post treatment with allogeneic CAR T cell product